The primary purpose of the Core B facility is to provide researchers of the P01 with rapid and cost effectivehigh throughput screening and molecular modeling of their targets with the ultimate goal of identifying 'hits'for further chemical lead optimization and biological characterization. The Core B facility comprises twofunctional units: Experimental HTS and Virtual HTS/ Molecular Modeling. The two units work closely togetherto provide complementary approaches toward screening biomolecular targets and toward aiding the leadoptimization process by serving as a resource for molecular modeling studies. The specific functions of CoreB include: 1) Experimental HTS: To screen the chemical libraries prepared by projects 1, 2, 3, 4 and 5 aswell as in-house chemical libraries to identify compounds capable of inhibiting SHP2 and chymotrypsin-likeproteasome activities as well as Rb/Raf, Bcl-xL/Bax and MDM2/MDMX/p53 associations. Our in-housechemical libraries include the publicly available NCI Diversity, Natural Product, Challenge and MechanisticSets as well as a 20,000 diverse chemical compound library we purchased from Chemical Diversity Labs(ChemDiv). The 20,000 compounds were selected from ChemDiv's ~600,000 compound collection, whichconsists of ChemDiv's internal synthesis efforts as well as procurement from laboratories around the world ,to represent maximal chemical and structural diversity. Experimental assays will also be preformed for theevaluation of ADME properties. 2) Virtual HTS: To search compound databases (-650,000 3D models)based on the X-ray or NMR structures of SHP2, MDM2, Bcl-xL and the chymotrypsin-like subunit of theproteasome. 3) Molecular Modeling: The best scoring compounds from virtual screening and, in particularthe experimentally confirmed 'hits' from virtual screening, will be subjected to additional molecular modelingstudies including 3D QSAR analysis to aid the lead optimization process. 4) Prediction of ADME Properties:The QikProp computer program (Schrodinger, L.L.C.) will be employed for the in silica prediction of ADMEproperties of 'hits' and to optimize ADME properties of potential drug candidates. 5) Data analysis andmanagement: To facilitate communication among projects 1, 2, 3, 4 and 5 and Core A, B and C, we have setup a centralized database for all related scientific data, The maintenance of the infra-structure of thedatabase is supported by the Moffitt IT Core Facility. Core B will be responsible for the management of thecontent of the databases. The database will allow users a) to register and track all compounds prepared byprojects 1,2,3,4 and 5 from synthesis/acquiring, shipment to testing; b) to search and review chemical andbiological data from projects 1, 2, 3, 4, 5 and Core B and C.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA118210-01A1
Application #
7214571
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O4))
Project Start
2006-12-01
Project End
2011-11-30
Budget Start
2007-02-05
Budget End
2008-01-31
Support Year
1
Fiscal Year
2007
Total Cost
$185,937
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Kazi, Aslamuzzaman; Ozcan, Sevil; Tecleab, Awet et al. (2014) Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem 289:11906-15
Ozcan, Sevil; Kazi, Aslamuzzaman; Marsilio, Frank et al. (2013) Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors. J Med Chem 56:3783-805
Treviño, José G; Verma, Monika; Singh, Sandeep et al. (2013) Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity. Mol Cancer Ther 12:2722-34
Ge, Yiyu; Kazi, Aslamuzzaman; Marsilio, Frank et al. (2012) Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. J Med Chem 55:1978-98
Davis, Rebecca; Pillai, Smitha; Lawrence, Nicholas et al. (2012) TNF-?-mediated proliferation of vascular smooth muscle cells involves Raf-1-mediated inactivation of Rb and transcription of E2F1-regulated genes. Cell Cycle 11:109-18
Kim, Young B; Balasis, Maria E; Doi, Kenichiro et al. (2012) Synthesis and evaluation of substituted hexahydronaphthalenes as novel inhibitors of the Mcl-1/BimBH3 interaction. Bioorg Med Chem Lett 22:5961-5
Johnson, Jackie L; Pillai, Smitha; Pernazza, Danielle et al. (2012) Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res 72:516-26
Doi, Kenichiro; Li, Rongshi; Sung, Shen-Shu et al. (2012) Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 287:10224-35
Li, X; Gilkes, D; Li, B et al. (2012) Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene 31:3721-32
Win-Piazza, Hla; Schneeberger, Valentina E; Chen, Liwei et al. (2012) Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2. Cancer Lett 320:81-5

Showing the most recent 10 out of 39 publications